Synthesis of taurolidine, purity profiles and polymorphs
US11738120B1 · kind B1 · utility
0Cited by
66References
24Claims
0Family size
Assignee
Inventor
Key dates
| Filing date | Apr 15, 2022 |
| Grant date | Aug 29, 2023 |
| Priority date | — |
| Expiry date | Apr 15, 2042 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61L2300/404
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Improved methods for synthesizing taurolidine, improved compositions or formulations comprising taurolidine and methods for reducing an amount of impurities in taurolidine are provided herein, among other things. The taurolidine may be substantially free of impurities. The taurolidine may be a polymorph, for example, Polymorph A or Polymorph B. The composition or formulation may comprise Low-Molecular-Weight (LMW) Heparin.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.